GHK vs SS-31

Evidence-based comparison · Updated 2026

Summary

GHK and SS-31 address fundamentally different biological targets. GHK is best suited for dermatological and wound-healing applications, promoting collagen synthesis and skin remodeling at the tissue level. SS-31 is the stronger choice for conditions involving mitochondrial dysfunction, cardiac stress, or neuroprotection. Neither is superior overall; the decision depends entirely on whether the research goal is tissue repair versus cellular energy restoration.

Side-by-Side Comparison

	GHK	SS-31
Evidence	BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries	BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries
Regulatory	Research OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only	Research OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only
Benefits	+Promotes skin healing +Anti-aging effects +Increases collagen and elastin +Reduces fine lines and wrinkles +Antioxidant properties	+Restores mitochondrial energy production +Protects cardiac tissue from damage +Supports neuroprotection in neurological conditions +Reduces oxidative stress in cells +Improves cellular ATP synthesis
Dosage	1-3 mg mg — Daily	0.25-5 mg — 1x daily
Route	Subcutaneous, Topical	Topical
Category	Skin & Anti-Aging	Skin & Anti-Aging

Full research page

GHK →

Full research page

SS-31 →

Which Should You Choose?

GHK operates primarily through fibroblast activation, growth factor modulation, and extracellular matrix remodeling, making it a tissue-level intervention. SS-31 acts at the inner mitochondrial membrane by stabilizing cardiolipin and restoring electron transport chain function, making it a subcellular, bioenergetic intervention.

Choose GHK when:

+Research focus is on skin repair, wound healing, or anti-aging outcomes where collagen and elastin production are primary endpoints.
+The target application involves dermal fibroblast activity, skin barrier function, or reduction of fine lines without a systemic energy component.
+Hair growth support or topical dermatological applications are within the scope of investigation.

Choose SS-31 when:

+Research focus involves mitochondrial dysfunction, reduced ATP synthesis, or conditions where oxidative phosphorylation is impaired.
+The target condition includes cardiac ischemia-reperfusion injury, heart failure, or neurodegenerative conditions where cardiolipin integrity is a relevant mechanism.
+Improving exercise tolerance or studying recovery from ischemic injury requires a mitochondrial-targeted approach that GHK does not provide.

Stacking GHK with SS-31 is not a commonly reported combination in the literature, as the two peptides operate in distinct biological compartments, tissue remodeling versus mitochondrial bioenergetics, with minimal mechanistic overlap.

Frequently Asked Questions

Do GHK and SS-31 have any overlapping mechanisms that would make combining them redundant?⌄

Both peptides demonstrate antioxidant properties, but through different pathways. GHK reduces oxidative stress primarily by modulating inflammatory signaling and supporting tissue repair enzymes at the extracellular level, while SS-31 reduces reactive oxygen species directly at the inner mitochondrial membrane by stabilizing the cardiolipin-cytochrome c complex. Because their antioxidant actions operate in different cellular compartments, combining them is unlikely to produce redundancy, though co-administration research remains limited.

How do the research timelines for observable effects differ between GHK and SS-31?⌄

In preclinical and early clinical research, GHK-related outcomes such as collagen upregulation and wound closure improvements have been observed over days to weeks of topical or subcutaneous application. SS-31 has shown acute cardioprotective effects in ischemia-reperfusion models within hours of administration, reflecting its rapid mitochondrial targeting. The timelines are not directly comparable because the two peptides are studied in entirely different experimental contexts and outcome measures.

If a research model involves both skin aging and metabolic decline, is there a rationale for using both GHK and SS-31?⌄

There is a theoretical rationale, as aging involves both extracellular matrix degradation, which GHK may address, and mitochondrial dysfunction contributing to reduced cellular energy and repair capacity, which SS-31 targets. Some researchers propose that restoring mitochondrial function via SS-31 could enhance the cellular environment that supports GHK-driven fibroblast activity, though no published studies have directly tested this combination in an aging model.

Which peptide has stronger clinical evidence supporting its primary use case?⌄

Both peptides carry a B evidence grade, meaning supportive preclinical data exist alongside limited or early-stage human trials. SS-31 (elamipretide) has advanced further into formal clinical development, with completed Phase II trials in heart failure with preserved ejection fraction, giving it a more structured human data profile for its primary cardiac application. GHK's human evidence base is concentrated in smaller dermatology studies and cosmetic formulation research, making direct clinical comparison difficult given the entirely different therapeutic domains.

Not sure which fits your research goals?

Use the Goal Finder

Answer 3 questions and get a personalised peptide recommendation ranked by evidence grade.

Find My Peptide →

More Comparisons

bpc 157 vs tb 500 mots c vs semaglutide dsip vs melanotan ii retatrutide vs tirzepatide cjc 1295 vs ipamorelin